4-Methylumbelliferyl 6-thio-Palmitate-β-D-Glucopyranoside | CAS 229644-17-1

4-Methylumbelliferyl 6-thio-Palmitate-β-D-Glucopyranoside, a fluorogenic substrate utilized in various biochemical and diagnostic settings, exhibits diverse applications. Here are four key applications:

Enzyme Activity Assays: Serving as a substrate for measuring β-D-glucosidase enzyme activity, this compound undergoes enzymatic cleavage, resulting in the release of the fluorescent product 4-methylumbelliferone. This product can be quantified with ease using fluorescence spectroscopy, providing researchers with a sensitive tool to monitor enzyme kinetics and screen for enzyme inhibitors or activators. The ability to precisely track enzymatic reactions aids in unraveling enzyme functionality and modulation within biological systems.

Lysosomal Storage Disorder Diagnostics: Utilized in diagnostic assays for lysosomal storage disorders like Gaucher and Fabry diseases, 4-Methylumbelliferyl 6-thio-Palmitate-β-D-Glucopyranoside enables clinicians to diagnose these genetic conditions promptly and accurately by measuring enzymatic activity in patient samples. Early and precise diagnosis is crucial for facilitating timely interventions and effective disease management, highlighting the significance of this substrate in clinical diagnostics.

Biochemical Research: An invaluable tool for studying glycosylation processes, this substrate plays a pivotal role in exploring the function and regulation of β-D-glucosidase enzymes. Researchers leverage its properties to investigate how changes in these enzymes impact cellular metabolism and disease states. The reliable fluorescence-based detection method empowers scientists to meticulously track enzyme activities within intricate biological samples, shedding light on the intricacies of enzyme modulation and cellular pathways.

High-Throughput Screening: Employed in high-throughput screening platforms for drug discovery, 4-Methylumbelliferyl 6-thio-Palmitate-β-D-Glucopyranoside facilitates the identification of potential therapeutic compounds that modulate enzyme activity. The substrate’s fluorogenic nature enables rapid and automated detection of positive hits, expediting the process of discovering novel drug candidates for diseases involving β-D-glucosidase enzymes. This streamlined approach accelerates the search for promising therapeutic agents, driving advancements in pharmacological research and drug development.